SSH.COM
7.6.2019 09:02:04 CEST | Business Wire | Press release
SSH.COM today announced that their access management gateway solution, PrivX , is now available for free in limited host environments to give IT and software teams all over the world the opportunity to enjoy the benefits of lean, scalable and automated access management to hybrid and multi-cloud (AWS, GCP, Azure, OpenStack) servers and applications.
Cloudification has changed the face of software development and deployment and IT management; modern techniques in software delivery require that trusted access management is in lockstep with development cycles, such as those used in the Continuous Integration/Continuous Delivery (CI/CD) models, while servers are located across on-prem, virtual private cloud (VPC) and multi-cloud environments. Extra steps, bottlenecks and manual processes simply don’t fit into that equation; it’s all about elasticity and automation.
SSH.COM’s Chief Customer Officer, Sami Ahvenniemi: “Spurred on by the shift to the cloud, we have identified that many our customers are looking for the following types of solutions:
- Modern and lean administrative access management tools
- Zero Trust solutions that manage access to critical assets, inside the perimeter
- Automated, scalable alternatives to in-house jump hosts and VPNs
- Centralized 3rd party access controls with monitoring and session recording
The focus is now on the entire access lifecycle of employees, including new hires, people moving around the organization, and people leaving the company. For example, developers, admins and external contractors are all needed - often temporarily - for various tasks with different levels of privilege, all within the critical IT infrastructure. Further, companies and teams often want to start small and scale IT management tools as needed, without taking on the burden of massive IT projects or turning their infrastructure into a hard-to-maintain and complex system. With PrivX, they get an access management solution that deploys in a matter of days, practically updates itself, provides monitoring of access traffic and delivers a simple user experience.”
SSH.COM’s PrivX offers just-in-time role-based access controls to multi-cloud and on-premises resources in development and production environments. Access authorization is never permanent but is based on short-lived certificates that expire within a few minutes of establishing the RDP/SSH connection. PrviX is an agentless and credentialess solution that integrates with existing identity access management (IAM) and directory service (AD/LDAP) tools as well as cloud-hosted servers and applications, including auto-discovery of cloud hosts.
SSH.COM is now making PrivX available free of charge online . Companies can start small and scale with PrivX as their business needs grow.
Mr. Ahvenniemi continued, “Cloud and hybrid environments require technological solutions that emphasize speed and agility over legacy products that are patched up to fit the needs of the cloud. That is why we built PrivX.”
Learn more about PrivX:
- Visit our PrivX product page .
- Download the PrivX datasheet .
- PrivX is reviewed in Kuppinger Cole’s Executive View Report .
- Read about PrivX and its ephemeral certificate-based authentication in our white paper .
About SSH.COM
SSH.COM helps organizations access, secure and control their digital core – their critical data, applications and services. We have over 3,000 customers around the world, including 40 percent of Fortune 500 companies, many of the world’s largest financial institutions, and major organizations in all verticals. We are committed to helping our customers thrive in the cloud era with solutions that offer secure access with zero inertia, zero friction and zero credentials risk. SSH.COM sells online; through offices in North America, Europe and Asia; and through a global network of certified partners. The company’s shares (SSH1V) are quoted on the NASDAQ Helsinki. For more information, visit www.ssh.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005053/en/
Contact:
SSH.COM Contact : Simo Karkkulainen SSH.COM +358 40 738 9406 simo.karkkulainen@ssh.com SSH.COM Agency Contact : Hanah Johnson March Communications +1 617-960-8892 ssh@marchcomms.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom